Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Kenneth F. Grossmann's publication output changed over time?
ScholarIQpublication output · 2015
3
2015
What are the most-cited papers on Kenneth F. Grossmann?
ScholarIQmost cited works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B.A.G. Haanen, Michele Maio, Iván Márquez‐Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth F. Grossmann, Mario Sznol, Brigitte Dréno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine E. Horak, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20158,191 CitationsOPEN ACCESS
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi
New England Journal of Medicine. 20152,774 CitationsOPEN ACCESS
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,672 Citations
Related on ScholarIQ
University of Utah
University
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Paper
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Paper
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Paper
Gut microbiota and health
Topic
Immunotherapy and Immune Responses
Topic